Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Actelion provides update on the DUAL program

Dec. 3, 2013

Lycera Corp. and Merck & Co. divulge novel RORgamma antagonists

Nov. 29, 2013

CleveXel and Dynamix to develop new treatment for rheumatoid arthritis

Nov. 27, 2013

Sanofi and Regeneron report phase III data for sarilumab in rheumatoid arthritis

Nov. 25, 2013

Horizon Pharma to acquire U.S. rights to Vimovo

Nov. 20, 2013

Results from phase IIIb study of Xiaflex for Dupuytren's contracture with multiple palpable cords

Nov. 19, 2013

Lupin discloses novel CRAC modulators

Nov. 19, 2013

A comparison of systemic and macrophage receptor-targeted delivery of an anti-inflammatory drug

Nov. 19, 2013

Ajinomoto patents novel integrin alpha4beta7 receptor antagonists

Nov. 18, 2013

Japanese researchers present novel Toll-like receptor antagonists

Nov. 15, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....